2024
IL-1 receptor 1 signaling shapes the development of viral antigen-specific CD4+ T cell responses following COVID-19 mRNA vaccination
Park H, Shin M, Shin J, Kim H, Kang B, Par-Young J, Unlu S, Afinogenova Y, Catanzaro J, Young J, Kim M, Lee S, Jeon S, You S, Racke M, Bucala R, Kang I. IL-1 receptor 1 signaling shapes the development of viral antigen-specific CD4+ T cell responses following COVID-19 mRNA vaccination. EBioMedicine 2024, 103: 105114. PMID: 38640835, PMCID: PMC11041015, DOI: 10.1016/j.ebiom.2024.105114.Peer-Reviewed Original ResearchConceptsCD4<sup>+</sup> T cellsCOVID-19 mRNA vaccinesAntigen-specific CD4<sup>+</sup> T cell responsesT cell responsesPrimary antibody deficiencyCD4<sup>+</sup> T cell responsesT cellsIL-1R1MRNA vaccinesIL-1IgG antibodiesAntigen-specific CD4<sup>+</sup> T cellsCD4+ T cell responsesLevels of IL-1R1Human CD4<sup>+</sup> T cellsIL-1 receptor 1Healthy individualsDose of COVID-19 mRNA vaccineAntigen-specific CD4IL-1R1 expressionT cell immunityRepetitive antigenic stimulationCytokines interleukin (IL)-1Immune response to virusesExpression of IL-1R1COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report
McDonnell J, Cousins K, Younger M, Lane A, Abolhassani H, Abraham R, Al-Tamemi S, Aldave-Becerra J, Al-Faris E, Alfaro-Murillo A, AlKhater S, Alsaati N, Doss A, Anderson M, Angarola E, Ariue B, Arnold D, Assa’ad A, Aytekin C, Bank M, Bergerson J, Bleesing J, Boesing J, Bouso C, Brodszki N, Cabanillas D, Cady C, Callahan M, Caorsi R, Carbone J, Carrabba M, Castagnoli R, Catanzaro J, Chan S, Chandra S, Chapdelaine H, Chavoshzadeh Z, Chong H, Connors L, Consonni F, Correa-Jimenez O, Cunningham-Rundles C, D’Astous-Gauthier K, Delmonte O, Demirdag Y, Deshpande D, Diaz-Cabrera N, Dimitriades V, El-Owaidy R, ElGhazali G, Al-Hammadi S, Fabio G, Faure A, Feng J, Fernandez J, Fill L, Franco G, Frenck R, Fuleihan R, Giardino G, Galant-Swafford J, Gambineri E, Garabedian E, Geerlinks A, Goudouris E, Grecco O, Pan-Hammarström Q, Khani H, Hammarström L, Hartog N, Heimall J, Hernandez-Molina G, Horner C, Hostoffer R, Hristova N, Hsiao K, Ivankovich-Escoto G, Jaber F, Jalil M, Jamee M, Jean T, Jeong S, Jhaveri D, Jordan M, Joshi A, Kalkat A, Kanarek H, Kellner E, Khojah A, Khoury R, Kokron C, Kumar A, Lecerf K, Lehman H, Leiding J, Lesmana H, Lim X, Lopes J, López A, Tarquini L, Lundgren I, Magnusson J, Marinho A, Marseglia G, Martone G, Mechtler A, Mendonca L, Milner J, Mustillo P, Naderi A, Naviglio S, Nell J, Niebur H, Notarangelo L, Oleastro M, Ortega-López M, Patel N, Petrovic G, Pignata C, Porras O, Prince B, Puck J, Qamar N, Rabusin M, Raje N, Regairaz L, Risma K, Ristagno E, Routes J, Roxo-Junior P, Salemi N, Scalchunes C, Schuval S, Seneviratne S, Shankar A, Sherkat R, Shin J, Siddiqi A, Signa S, Sobh A, Lima F, Stenehjem K, Tam J, Tang M, Barros M, Verbsky J, Vergadi E, Voelker D, Volpi S, Wall L, Wang C, Williams K, Wu E, Wu S, Zhou J, Cook A, Sullivan K, Marsh R. COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report. Journal Of Clinical Immunology 2024, 44: 86. PMID: 38578389, PMCID: PMC10997719, DOI: 10.1007/s10875-023-01613-5.Peer-Reviewed Original ResearchConceptsInborn errors of immunityCOVID-19 vaccineICU admissionInborn errors of immunity patientsInborn errorsUS Immunodeficiency NetworkErrors of immunityVaccination prior to infectionLogistic regression analysisVaccine safetyAntibody deficiencyRates of hospitalizationCOVID-19 severitySymptomatic anemiaOdds of hospitalizationCOVID-19 infectionRegistry databaseMRNA-basedCOVID-19 vaccine safetyPatientsOutpatient clinicEmergency room careICU careICUVaccine
2022
Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients
Ünlü S, Shin J, Par-Young J, Simonov M, Vinetz J, Petrylak D, Kang I, Kim J. Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients. Cancer Investigation 2022, 41: 77-83. PMID: 36373994, DOI: 10.1080/07357907.2022.2139839.Peer-Reviewed Original ResearchConceptsProstate cancer patientsCOVID-19 outcomesCancer patientsPoor COVID-19 outcomesAndrogen-androgen receptorExpression of TMPRSS2COVID-19 infectionSARS-CoV-2Directed therapyMean hospitalizationPCa patientsHospitalization ratesPCa casesRetrospective analysisOutcome differencesPatientsDefinitive conclusionsStatistical significanceData generate hypothesesHospitalizationTherapyTMPRSS2Cellular entryOutcomesARDTMIF is a common genetic determinant of COVID-19 symptomatic infection and severity
Shin JJ, Fan W, Par-Young J, Piecychna M, Leng L, Israni-Winger K, Qing H, Gu J, Zhao H, Schulz WL, Unlu S, Kuster J, Young G, Liu J, Ko AI, Garcia A, Sauler M, Wisnewski AV, Young L, Orduña A, Wang A, Klementina O, Garcia AB, Hegyi P, Armstrong ME, Mitchell P, Ordiz DB, Garami A, Kang I, Bucala R. MIF is a common genetic determinant of COVID-19 symptomatic infection and severity. QJM 2022, 116: 205-212. PMID: 36222594, PMCID: PMC9620729, DOI: 10.1093/qjmed/hcac234.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorLow-expression MIF alleleCOVID-19 infectionMIF allelesCATT7 alleleHealthy controlsCOVID-19Serum macrophage migration inhibitory factorSymptomatic SARS-CoV-2 infectionHigher serum MIF levelsHigh-expression MIF allelesRetrospective case-control studySARS-CoV-2 infectionFunctional polymorphismsAvailable clinical characteristicsMultinational retrospective studySerum MIF levelsUninfected healthy controlsSymptomatic COVID-19Tertiary medical centerHealthy control subjectsCase-control studyMigration inhibitory factorCoronavirus disease 2019Common functional polymorphismsDefining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency
Shin JJ, Par-Young J, Unlu S, McNamara A, Park HJ, Shin MS, Gee RJ, Doyle H, Afinogenova Y, Zidan E, Kwah J, Russo A, Mamula M, Hsu FI, Catanzaro J, Racke M, Bucala R, Wilen C, Kang I. Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency. Journal Of Clinical Immunology 2022, 42: 1137-1150. PMID: 35713752, PMCID: PMC9203263, DOI: 10.1007/s10875-022-01296-4.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ViralCD8-Positive T-LymphocytesCommon Variable ImmunodeficiencyCOVID-19COVID-19 VaccinesHumansImmunity, CellularImmunoglobulin AImmunoglobulin GMRNA VaccinesPrimary Immunodeficiency DiseasesRNA, MessengerSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationVaccinesVaccines, SyntheticConceptsCommon variable immune deficiencyT cellsImmune responseIgG responsesCVID patientsMRNA vaccinesB cellsCoronavirus disease 2019 (COVID-19) mRNA vaccinesCOVID-19 mRNA vaccinesBaseline immune profileHistory of autoimmunityPrimary antibody deficiencyT cell responsesCellular immune responsesPoor immune responseVariable immune deficiencyMemory B cellsSARS-CoV-2 spike proteinBaseline IgGCVID diagnosisEM CD8Immunological predictorsPAD cohortSpecific CD4Immune profile
2021
Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency
Kuster JK, Unlu S, Makin TA, Par-Young J, Simonov M, Shafi S, Balanda M, Randolph C, Steele R, Hsu FI, Price C, Kohli-Pamnani A, Borish L, Lawrence MG, Kang I, Shin JJ. Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency. The Journal Of Allergy And Clinical Immunology In Practice 2021, 10: 633-636.e3. PMID: 34929372, PMCID: PMC8683251, DOI: 10.1016/j.jaip.2021.11.030.Peer-Reviewed Original ResearchA distinct association of inflammatory molecules with outcomes of COVID-19 in younger versus older adults
Shin JJ, Jeon S, Unlu S, Par-Young J, Shin MS, Kuster JK, Afinogenova Y, Kang Y, Simonov M, Buller G, Bucala R, Kang I. A distinct association of inflammatory molecules with outcomes of COVID-19 in younger versus older adults. Clinical Immunology 2021, 232: 108857. PMID: 34560283, PMCID: PMC8455237, DOI: 10.1016/j.clim.2021.108857.Peer-Reviewed Original ResearchConceptsClinical outcomesOlder adultsInflammatory moleculesHospitalized adult COVID-19 patientsOlder subjectsAdult COVID-19 patientsSoluble IL-2 receptor alphaIL-2 receptor alphaCOVID-19Different immunologic mechanismsAcute phase reactantsCOVID-19 patientsDevastating clinical outcomesT cell activationImmunologic mechanismsIL-10Immune agingInflammatory processImmune mechanismsPhase reactantsSevere diseaseReceptor alphaCell activationDisease severityBiological predictorsInfectious Complications Predict Premature CD8+ T-cell Senescence in CD40 Ligand-Deficient Patients
Shin JJ, Catanzaro J, Yonkof JR, Delmonte O, Sacco K, Shin MS, Reddy S, Whittington PJ, Soffer G, Mustillo PJ, Sullivan KE, Notarangelo LD, Abraham RS, Romberg N, Kang I. Infectious Complications Predict Premature CD8+ T-cell Senescence in CD40 Ligand-Deficient Patients. Journal Of Clinical Immunology 2021, 41: 795-806. PMID: 33495902, PMCID: PMC8329305, DOI: 10.1007/s10875-021-00968-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge of OnsetBiomarkersCase-Control StudiesCD40 LigandCD8-Positive T-LymphocytesCellular SenescenceChild, PreschoolGenes, X-LinkedGenetic Association StudiesGenetic Predisposition to DiseaseHumansImmune System DiseasesImmunophenotypingInfectionsPedigreePhenotypePrognosisReceptors, Antigen, T-CellYoung AdultConceptsT cell senescenceCD40L-deficient patientsImmunoglobulin G replacementHealthy controlsT cellsInfectious complicationsCD40L deficiencyT-cell receptor excision circle analysisPneumocystis jirovecii pneumonia prophylaxisCMV-specific proliferationPatient group 2Effector memory CD8Effective prophylactic strategyCytokine release assaysAdult healthy controlsEarly CD8Pneumonia prophylaxisProphylaxis adherenceResultsThree patientsProphylactic antibioticsSenescence-associated moleculesMemory CD8Childhood pneumoniaInfectious exposureRecurrent infections
2020
Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome
Azar MM, Shin JJ, Kang I, Landry M. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome. Expert Review Of Molecular Diagnostics 2020, 20: 1087-1097. PMID: 32990479, DOI: 10.1080/14737159.2020.1830760.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Immune profileCOVID-19SARS-CoV-2 infectionCytokine release syndromeAdaptive immune cellsMultiple inflammatory cytokinesSARS-CoV-2 RNAFalse-negative resultsRelease syndromeInfectious complicationsIL-10Laboratory markersD-dimerInflammatory moleculesIP-10IL-6Inflammatory cytokinesMCP-1Acute diagnosisIL-2Immune cellsClinical severityTherapeutic benefitPathogenic contributionImmunological and Clinical Phenotyping in Primary Antibody Deficiencies: a Growing Disease Spectrum
Shin JJ, Liauw D, Siddiqui S, Lee J, Chung EJ, Steele R, Hsu FI, Price C, Kang I. Immunological and Clinical Phenotyping in Primary Antibody Deficiencies: a Growing Disease Spectrum. Journal Of Clinical Immunology 2020, 40: 592-601. PMID: 32239366, PMCID: PMC7260109, DOI: 10.1007/s10875-020-00773-y.Peer-Reviewed Original ResearchConceptsCommon variable immunodeficiencyInterstitial lung diseasePrimary antibody deficiencyConnective tissue diseaseAntibody deficiencyLow NK cell countHematopoietic malignanciesNon-infectious complicationsNon-infectious manifestationsNK cell countsNatural killer cellsPneumococcal vaccine responsesElectronic medical recordsResultsAll patientsImmune alterationsVaccine responsesKiller cellsTissue diseaseImmunoglobulin levelsVariable immunodeficiencyLung diseasePAD groupIgG deficiencyImmunological profileMedical records